Loading…

Peptide nanovaccine in melanoma immunotherapy

[Display omitted] •Melanoma is a fatal neoplasm resistant to traditional treatment.•Recently peptide vaccine has obtained remarkable attention in treatment of melanoma.•Nanoparticles can incite a strong immunity to peptide-based melanoma vaccines. Melanoma is an especially fatal neoplasm resistant t...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2024-03, Vol.129, p.111543-111543, Article 111543
Main Authors: Dehghankhold, Mahvash, Sadat Abolmaali, Samira, Nezafat, Navid, Mohammad Tamaddon, Ali
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Melanoma is a fatal neoplasm resistant to traditional treatment.•Recently peptide vaccine has obtained remarkable attention in treatment of melanoma.•Nanoparticles can incite a strong immunity to peptide-based melanoma vaccines. Melanoma is an especially fatal neoplasm resistant to traditional treatment. The advancement of novel therapeutical approaches has gained attention in recent years by shedding light on the molecular mechanisms of melanoma tumorigenesis and their powerful interplay with the immune system. The presence of many mutations in melanoma cells results in the production of a varied array of antigens. These antigens can be recognized by the immune system, thereby enabling it to distinguish between tumors and healthy cells. In the context of peptide cancer vaccines, generally, they are designed based on tumor antigens that stimulate immunity through antigen-presenting cells (APCs). As naked peptides often have low potential in eliciting a desirable immune reaction, immunization with such compounds usually necessitates adjuvants and nanocarriers. Actually, nanoparticles (NPs) can provide a robust immune response to peptide-based melanoma vaccines. They improve the directing of peptide vaccines to APCs and induce the secretion of cytokines to get maximum immune response. This review provides an overview of the current knowledge of the utilization of nanotechnology in peptide vaccines emphasizing melanoma, as well as highlights the significance of physicochemical properties in determining the fate of these nanovaccines in vivo, including their drainage to lymph nodes, cellular uptake, and influence on immune responses.
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2024.111543